Joel Neal, MD, PhD

Publications

• A case series of NSCLC patients with different molecular characteristics and choroidal metastases: improvement in vision with treatment including pemetrexed and bevacizumab. Riess JW, Nagpal S, Das M, Neal JW, Kim JW, Wakelee HA. J Thorac Oncol. 2013; 8 (2): e17-8
• Aflibercept in lung cancer. Neal JW, Wakelee HA. Expert Opin Biol Ther. 2013; 13 (1): 115-20
• A phase I study of erlotinib and hydroxychloroquine in advanced non-small-cell lung cancer. Goldberg SB, Supko JG, Neal JW, Muzikansky A, Digumarthy S, Fidias P, Temel JS, Heist RS, Shaw AT, McCarthy PO, Lynch TJ, Sharma S, Settleman JE, Sequist LV. J Thorac Oncol. 2012; 7 (10): 1602-8
• Complex role of histone deacetylase inhibitors in the treatment of non-small-cell lung cancer. Neal JW, Sequist LV. J Clin Oncol. 2012; 30 (18): 2280-2
• First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors. Nguyen KS, Neal JW. Biologics. 2012: 6 337-45
• Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. Lynch TJ, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R, Sebastian M, Neal J, Lu H, Cuillerot JM, Reck M. J Clin Oncol. 2012; 30 (17): 2046-54
• Targeting fibroblast growth factor receptor and discoidin domain receptor 2 in non-small-cell lung cancer. Riess JW, Neal JW. J Thorac Oncol. 2012; 7 (16 Suppl 5): S385-6
• Current management of small cell lung cancer. Neal JW, Gubens MA, Wakelee HA. Clin Chest Med. 2011; 32 (4): 853-63
• One allele's loss is another's gain: alterations of NKX2-8 in non-small cell lung cancer. Neal JW, Shaw AT. Clin Cancer Res. 2011; 17 (4): 638-9
• Targeting FGFR, ephrins, Mer, MET, and PDGFR-α in non-small cell lung cancer. Riess JW, Neal JW. J Thorac Oncol. 2011; 6 (11 Suppl 4): S1797-8
• AMG-386, a selective angiopoietin-1/-2-neutralizing peptibody for the potential treatment of cancer. Neal J, Wakelee H. Curr Opin Mol Ther. 2010; 12 (4): 487-95
• Exciting new targets in lung cancer therapy: ALK, IGF-1R, HDAC, and Hh. Neal JW, Sequist LV. Curr Treat Options Oncol. 2010; 11 (1-2): 36-44
• Targeted therapies: optimal first-line therapy for NSCLC with EGFR mutations. Neal JW, Sequist LV. Nat Rev Clin Oncol. 2010; 7 (2): 71-2
• The SATURN trial: the value of maintenance erlotinib in patients with non-small-cell lung cancer. Neal JW, Future Oncol. 2010; 6 (12): 1827-32
• A constitutively active NFATc1 mutant induces a transformed phenotype in 3T3-L1 fibroblasts. Neal JW, Clipstone NA. J Biol Chem. 2003; 278 (19): 17246-54
• Induction of FucT-VII by the Ras/MAP kinase cascade in Jurkat T cells. Barry SM, Zisoulis DG, Neal JW, Clipstone NA, Kansas GS. Blood. 2003; 102 (5): 1771-8
• Calcineurin mediates the calcium-dependent inhibition of adipocyte differentiation in 3T3-L1 cells. Neal JW, Clipstone NA. J Biol Chem. 2002; 277 (51): 49776-81
• Glycogen synthase kinase-3 inhibits the DNA binding activity of NFATc. Neal JW, Clipstone NA. J Biol Chem. 2001; 276 (5): 3666-73
• Regulation of the glucose:H+ symporter by metabolite-activated ATP-dependent phosphorylation of HPr in Lactobacillus brevis. Ye JJ, Neal JW, Cui X, Reizer J, Saier MH. J Bacteriol. 1994; 176 (12): 3484-92